Sandbox:Preeti: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 65: Line 65:
! colspan="24" align="left" style="background:#4479BA; color: #FFFFFF;" + |NHL
! colspan="24" align="left" style="background:#4479BA; color: #FFFFFF;" + |NHL
|-
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |B Cell Lymphoma
! rowspan="12" align="center" style="background:#4479BA; color: #FFFFFF;" + |B Cell Lymphoma
! colspan="2" align="center" style="background:#DCDCDC;" + |B-lymphoblastic leukemia/lymphoma  
! colspan="2" align="center" style="background:#DCDCDC;" + |B-lymphoblastic leukemia/lymphoma  
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
Line 80: Line 80:
* Ionizing radiation
* Ionizing radiation
* Chemotherapy
* Chemotherapy
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |–
| align="center" style="background:#F5F5F5;" + |–
| align="center" style="background:#F5F5F5;" + |–
| align="center" style="background:#F5F5F5;" + |–
Line 104: Line 104:
* Down syndrome
* Down syndrome
|-
|-
!
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Follicular lymphoma]]
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Follicular lymphoma]]
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
Line 153: Line 152:
* Peripheral nerve compression
* Peripheral nerve compression
|-
|-
!
! colspan="2" align="center" style="background:#DCDCDC;" + |Mantle cell lymphoma
! colspan="2" align="center" style="background:#DCDCDC;" + |Mantle cell lymphoma
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
Line 195: Line 193:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!
! colspan="2" align="center" style="background:#DCDCDC;" + |Diffuse large B cell lymphoma
! colspan="2" align="center" style="background:#DCDCDC;" + |Diffuse large B cell lymphoma
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
Line 238: Line 235:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Category
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology
Line 262: Line 258:
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings
|-
|-
!
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Burkitt lymphoma]]
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Burkitt lymphoma]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 309: Line 304:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!
! colspan="2" align="center" style="background:#DCDCDC;" + |B cell chronic lymphocytic leukemia/small lymphocytic lymphoma
! colspan="2" align="center" style="background:#DCDCDC;" + |B cell chronic lymphocytic leukemia/small lymphocytic lymphoma
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
Line 334: Line 328:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!
! rowspan="3" align="center" style="background:#DCDCDC;" + |Marginal zone lymphoma
! rowspan="3" align="center" style="background:#DCDCDC;" + |Marginal zone lymphoma
! align="center" style="background:#DCDCDC;" + |Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type
! align="center" style="background:#DCDCDC;" + |Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type
Line 360: Line 353:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
|
! align="center" style="background:#DCDCDC;" + |[[Splenic marginal zone lymphoma]]
! align="center" style="background:#DCDCDC;" + |[[Splenic marginal zone lymphoma]]
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
Line 394: Line 386:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
|
! align="center" style="background:#DCDCDC;" + |[[Nodal marginal zone B-cell lymphoma]]  
! align="center" style="background:#DCDCDC;" + |[[Nodal marginal zone B-cell lymphoma]]  
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
Line 430: Line 421:
* Sjögren syndrome
* Sjögren syndrome
|-
|-
|
! colspan="2" align="center" style="background:#DCDCDC;" + |Lymphoplasmacytic lymphoma (Waldenstrom’s macroglobulinemia)
! colspan="2" align="center" style="background:#DCDCDC;" + |Lymphoplasmacytic lymphoma (Waldenstrom’s macroglobulinemia)
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
Line 455: Line 445:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
|
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Hairy cell leukemia]]
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Hairy cell leukemia]]
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
Line 511: Line 500:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
|
| rowspan="10" |T cell lymphoma
! colspan="2" align="center" style="background:#DCDCDC;" + |Precursor T-cell lymphoblastic leukemia/lymphoma
! colspan="2" align="center" style="background:#DCDCDC;" + |Precursor T-cell lymphoblastic leukemia/lymphoma
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
Line 536: Line 525:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
|
! colspan="2" align="center" style="background:#DCDCDC;" + |Adult T cell leukemia/lymphoma
! colspan="2" align="center" style="background:#DCDCDC;" + |Adult T cell leukemia/lymphoma
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
Line 561: Line 549:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
|T cell lymphoma
! colspan="2" align="center" style="background:#DCDCDC;" + |Anaplastic large cell lymphoma
! colspan="2" align="center" style="background:#DCDCDC;" + |Anaplastic large cell lymphoma
| align="left" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
Line 586: Line 573:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
|
! align="center" style="background:#DCDCDC;" + |Cutaneous T-cell lymphoma
! align="center" style="background:#DCDCDC;" + |Cutaneous T-cell lymphoma
! align="center" style="background:#DCDCDC;" + |[[Mycosis fungoides]] / [[Sézary syndrome]]
! align="center" style="background:#DCDCDC;" + |[[Mycosis fungoides]] / [[Sézary syndrome]]
Line 625: Line 611:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
|
! rowspan="6" align="center" style="background:#DCDCDC;" + |Peripheral T-cell lymphoma
! rowspan="6" align="center" style="background:#DCDCDC;" + |Peripheral T-cell lymphoma
! align="center" style="background:#DCDCDC;" + |Subcutaneous panniculitis-like T-cell lymphoma
! align="center" style="background:#DCDCDC;" + |Subcutaneous panniculitis-like T-cell lymphoma
Line 651: Line 636:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
|
! align="center" style="background:#DCDCDC;" + |Hepatosplenic gamma-delta T-cell lymphoma
! align="center" style="background:#DCDCDC;" + |Hepatosplenic gamma-delta T-cell lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 676: Line 660:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
|
! align="center" style="background:#DCDCDC;" + |Enteropathy-type intestinal T-cell lymphoma
! align="center" style="background:#DCDCDC;" + |Enteropathy-type intestinal T-cell lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 701: Line 684:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
|
! align="center" style="background:#DCDCDC;" + |Extranodal T-cell lymphoma, nasal type
! align="center" style="background:#DCDCDC;" + |Extranodal T-cell lymphoma, nasal type
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 726: Line 708:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
|
! align="center" style="background:#DCDCDC;" + |Angioimmunoblastic T-cell lymphoma
! align="center" style="background:#DCDCDC;" + |Angioimmunoblastic T-cell lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 751: Line 732:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
|
! align="center" style="background:#DCDCDC;" + |Peripheral T-cell lymphoma, unspecified
! align="center" style="background:#DCDCDC;" + |Peripheral T-cell lymphoma, unspecified
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |

Revision as of 16:02, 17 January 2019


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Preeti Singh, M.B.B.S.[2]

Category Disease Etiology Clinical manifestations Paraclinical findings Gold standard Associated findings
Lab findings
Demography History Symptoms Signs CBC PBS PT/PTT Immunochemistry Histopathology Other
Constitutional symptoms Rash Abdominal pain Diarrhea V/S Mass Hepatosplenomegaly Other WBC Hb Plt
HL
Hodgkin's Lymphoma
NHL
B Cell Lymphoma B-lymphoblastic leukemia/lymphoma
  • Precursor B-cell Lymphoma
  • Unknown
  • Inherited mutations of PAX5, ETV6, and TP53
  • Most common in children <6 years old
  • Second peak in adults >60 years old
  • M>F
  • More in Whites and Hispanics
  • Ionizing radiation
  • Chemotherapy
+
  • Fever
± Nl to ↓
  • Down syndrome
Follicular lymphoma
  • Mature B-cell Lymphoma
  • Reciprocal translocation t(14;18)
  • Overexpression of BCL2
  • Second most common subtype of NHL
  • Whites>>African-americans or Asians
  • Median age at diagnosis of 65 years
  • Slightly positive family history
Only in 20% of patients: + + ± Nl
  • Painless peripheral adenopathy in the cervical, axillary, inguinal, and/or femoral regions
  • Asymptomatic large abdominal mass
+ Nl to ↓
  • Cytopenia
NA
  • CD21
  • CD23
  • Nodular growth pattern
  • Elevated LDH
Lymph node biopsy
  • Most common clinically indolent NHL
  • Peripheral nerve compression
Mantle cell lymphoma
  • Fatigue
  • Night sweats
  • Weight Loss
Abdominal distention
  • Palpable masses in skin, breast, and salivary glands
  • Generalized lymphadenopathy
+
  • Extranodal involvement of GI tract, lungs, and CNS
  • Mental Retardation
  • Lymphocytosis > 4000/µL
Nl to ↓
  • CD5+
  • B-cell antigen positive
  • Overexpression of Cyclin D1
  • Germinal centers filled by small-to-medium atypical lymphocytes
  • Nodular appearance
  • Elevated LDH
Diffuse large B cell lymphoma
  • Mature B-cell Lymphoma
  • 8q24/MYC translocations
  • Hypermutated immunoglobulin genes
  • Mutation of BCL6, MYC, PAX5, PIM1, RhoH /TTFn, TP53 genes
  • Translocations involving c-MYC, BCL6, and IgH gene.
  • Fever
  • Night sweats
  • weight loss
Nl to ↓

Centroblastic

Immunoblastic

  • > 90% immunoblasts
  • Trapezoid shaped large lymphoid cells with significant basophilic cytoplasm

Anaplastic

  • Very large cells with a round, oval, or polygonal shape that may resemble Reed-Sternberg cells
  • Hypergammaglobulinemia
Disease Etiology Demography History Constitutional symptoms Rash Abdominal pain Diarrhea V/S Mass Hepatosplenomegaly Other WBC Hb Plt PBS PT/PTT Immunochemistry Histopathology Other lab findings Gold standard Associated findings
Burkitt lymphoma
  • Mature B-cell Lymphoma
  • Translocation of chromosome 8 myc locus such as:
    • t(8;14)
    • t(2;8)
    • t(8;22)
  • Round and small nucleoli
  • basophilic cytoplasm
  • "Starry-sky pattern"
B cell chronic lymphocytic leukemia/small lymphocytic lymphoma
  • Mature B-cell Lymphoma
Marginal zone lymphoma Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type
  • Mature B-cell Lymphoma
Splenic marginal zone lymphoma
  • Mature B-cell Lymphoma
  • Clonal rearrangements of the immunoglobulin genes (heavy and light chains)
    • Deletion 7q21-32
    • Translocations of the CDK6 gene located on 7q21
  • Small lymphocytes
  • Transformed blasts
  • Epithelial histocytes
  • Plasmacytic differentiation of neoplastic cells
Nodal marginal zone B-cell lymphoma
  • Mature B-cell Lymphoma
  • Stimulation of antigen receptor by autoantigen and co-stimulatory molecule CD40
+
  • Hemorrhage
  • Dyspepsia
  • AE1/AE3
  • Expression of B-cell markers CD20, CD79a, CD10, CD23, and bcl-2
  • Follicular cells in reactive zone
  • Centrocyte like cells in marginal zone lymphoma
  • Chronic infectious conditions or autoimmune processes, such as
    • H pylori gastritis
  • Hashimoto thyroiditis
  • Sjögren syndrome
Lymphoplasmacytic lymphoma (Waldenstrom’s macroglobulinemia)
  • Mature B-cell Lymphoma
Hairy cell leukemia
  • Production of cytokines, such as TNF alpha and IL-2R, provide important stimuli for malignant B cells proliferation in hairy cell leukemia.
    • The p38-MAPK-JNK cascade
    • The MEK-ERK cascade
    • The Phosphatidylinositol 3 kinase (PI3K)-AKT cascade
  • Tartrate-resistant acid phosphatase positive
  • CBC
  • Small cells with "fried egg"-like appearance
  • Well-demarcated thread-like cytoplasmic extensions
  • Clear cytoplasm
  • Central round nucleus
  • Peri-nuclear clearing ("water-clear rim" appearance)
T cell lymphoma Precursor T-cell lymphoblastic leukemia/lymphoma
  • Precursor T-cell Lymphomas
Adult T cell leukemia/lymphoma
  • Mature T-cell Lymphoma
Anaplastic large cell lymphoma
  • Mature T-cell Lymphoma
Cutaneous T-cell lymphoma Mycosis fungoides / Sézary syndrome
  • Cutaneous manifestations
Peripheral T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma
  • Mature T-cell Lymphoma
Hepatosplenic gamma-delta T-cell lymphoma
  • Mature T-cell Lymphoma
Enteropathy-type intestinal T-cell lymphoma
  • Mature T-cell Lymphoma
Extranodal T-cell lymphoma, nasal type
  • Mature T-cell Lymphoma
Angioimmunoblastic T-cell lymphoma
  • Mature T-cell Lymphoma
Peripheral T-cell lymphoma, unspecified
  • Mature T-cell Lymphoma